← Back to Search

PARP Inhibitor

Cohort 1 for Solid Tumors

Phase 1 & 2

Recruiting

Research Sponsored by Eikon Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years at the time of informed consent

Breast cancer patients who have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, received hormonal therapy if HR+

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, up to 3 years

Awards & highlights

Study Summary

"This trial will test how well IMP1734 works in patients with advanced breast cancer, ovarian cancer, and prostate cancer that has come back or spread. The patients in the study will have specific genetic mutations

Who is the study for?

This trial is for adults with advanced breast, ovarian, or prostate cancer that has spread and have specific gene mutations. They must have tried platinum-based chemo (for ovarian cancer) or one chemo in any setting (for breast cancer), and may have had a PARP inhibitor before. Men must be on hormone therapy for prostate cancer and could've had taxane chemotherapy. All participants need to use birth control during the study.Check my eligibility

What is being tested?

The trial tests IMP1734's effectiveness specifically in patients with certain types of advanced cancers—breast, ovarian, or prostate—that are resistant to previous treatments and carry particular genetic mutations affecting DNA repair.See study design

What are the potential side effects?

While not explicitly listed here, side effects of IMP1734 might include typical reactions seen with similar drugs like nausea, fatigue, blood cell count changes leading to increased infection risk or bleeding tendencies, liver function alterations, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have breast cancer and have had chemotherapy or hormone therapy if my cancer is hormone receptor positive.

Select...

I have had platinum-based chemotherapy for my advanced ovarian, fallopian tube, or peritoneal cancer.

Select...

I am fully active or can carry out light work.

Select...

I have harmful genetic changes in specific DNA repair genes.

Select...

I have had one previous treatment that included a PARP inhibitor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maxim Tolerated Dose or Recommended Dose for Expansion

Number of subjects with adverse events, treatment emergent adverse events or serious adverse events

Secondary outcome measures

Overall Response Rate

Pharmacokinetic parameters of IMP1734

Other outcome measures

Characterization of the pharmacodynamic changes due to IMP1734

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cohort 1Experimental Treatment1 Intervention

IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Impact Therapeutics, Inc.Industry Sponsor

14 Previous Clinical Trials

1,534 Total Patients Enrolled

Eikon TherapeuticsLead Sponsor

5 Previous Clinical Trials

162 Total Patients Enrolled

Viola Chen, MDStudy DirectorEikon Therapeutics

2 Previous Clinical Trials

896 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of participants being recruited for this research endeavor?

"Affirmative. Information obtained from clinicaltrials.gov indicates that this investigation is actively seeking volunteers. The trial's initial posting was on December 11th, 2023, with the latest update on February 2nd, 2024. A total of 70 participants are sought across five distinct sites for enrollment in this study."

Answered by AI

Which individuals meet the eligibility criteria for participation in this research project?

"Individuals with solid neoplasms aged between 18 and 89 are eligible for this research project. The trial aims to recruit a cohort of 70 participants."

Answered by AI

Are eligible patients able to enroll in this ongoing trial at the present time?

"Indeed, the details on clinicaltrials.gov indicate that this research study is actively seeking candidates. The trial was first listed on December 11th, 2023 and last revised on February 2nd, 2024. Recruitment aims to enroll a total of 70 participants across five designated locations."

Answered by AI

Are multiple medical facilities in North America currently conducting this research study?

"Patients can enroll in this clinical trial at Sarah Cannon Research Institute Health One situated in Denver, Colorado; Sarah Cannon Research Institute Oncology located in Nashville, Tennessee; and START - South Texas Accelerated Research Therapeutics based in San Antonio, Texas. Additionally, there are openings available at five additional sites for interested participants."

Answered by AI

Is the trial accepting participants aged 80 and above?

"Participants aged between 18 and 89 are eligible for this study as per the inclusion criteria. It is noted that there are a total of 317 studies focusing on individuals under 18 years old, while there are 2489 studies targeting those over the age of 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

2023. "A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06253130.

All > Pflugerville Tx > Colorado Springs